The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Neuroendocrine tumor podcast explores neuroendocrine tumors (NETS), featuring world-renowned NET specialists and patients living with neuroendocrine cancer.
FDA approves Gallium-68 DOTATOC PET/CT, another new imaging agent, for use in scanning neuroendocrine tumors. Data showed Gallium-68 DOTATOC superior to decades-old methods for disease staging, treatment planning, and identifying unknown primary sites.
WIN Check Presentation to NETRF in honor of Aretha Franklin: (Left to right) Patricia A. Cole, WIN Founder, Julie Wash, Health Fair Chair, Susan Payson,
Aretha Franklin was a trailblazer. She broke barriers as the first woman welcomed into the Rock and Roll Hall of Fame and as the indisputable
Join Me in the Fight by Katherin Mueller As I write this, I am about eight months into my “new normal” aka living with NETs.
New grant explores precision drug delivery in NETs The American Association of Cancer Researchers (AACR) has awarded a NETRF-funded research grant to a Texas researcher
Life’s work of artist whose career was cut short by NET The Heritage of Sherborn, MA, will host a Retrospective Art Show and final sale
Coping with the uncertainty of a cancer diagnosis means finding ways to take your mind off cancer, to do what you enjoy most, finding meaning and purpose.
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.